Oncologic outcomes and renal function preservation after stereotactic ablative body radiotherapy versus radiofrequency ablation in stage I renal cell carcinoma Authors: Ye Jin Yoo, Lim Jiyoon, Kye Jin Park, Cheryn Song, Yeon Joo Kim, Young Seok Kim Published: 2026 ABSTRACT Highlights•SABR showed oncologic outcomes comparable to RFA after IPTW adjustment.•Longitudinal eGFR decline was similar despite lower baseline eGFR with SABR.•SABR remained effective despite older age and less favorable tumor features.•SABR is a viable treatment alternative to RFA for localized RCC.•Only one grade ≥ 3 non-renal toxicity: bleeding after marker insertion. Introduction Stage I renal cell carcinoma (RCC) is increasingly diagnosed in elderly patients [1] and those with significant comorbidities, in whom surgical resection may not be feasible [2]. Although partial nephrectomy remains the standard of care for operable patients, non-surgical local therapies have emerged as important alternatives for patients who are medically inoperable or decline surgery. Among these, radiofrequency ablation (RFA) has been widely adopted as a minimally invasive treatment option [3], [4]. RFA is associated with favorable oncologic outcomes in selected patients with small, peripherally located tumors. However, its efficacy may be limited in centrally located tumors abutting the renal hilum, proximal ureter, or major vessels, where the risk of incomplete ablation and procedure-related morbidity increases due to proximity to critical structures [5]. In addition, RFA is an invasive procedure that often requires general anesthesia or deep sedation, which may be suboptimal for frail patients with multiple comorbidities. SABR has emerged as a promising alternative for primary RCC, offering precise dose delivery with steep dose gradients and minimal damage to surrounding normal tissues. Although RCC was historically considered radioresistant based on outcomes with conventional fractionated radiotherapy [6], [7], recent studies have demonstrated excellent local control rates exceeding 90% with SABR, which delivers high doses per fraction [8], [9], including in tumors challenging for thermal ablation. Moreover, SABR avoids the need for anesthesia, which may be advantageous in high-risk patients. However, comparative data directly evaluating SABR against RFA remain limited. Moreover, renal function preservation is critical outcome in this population, yet comparative data adjusting for baseline renal function is scarce. Therefore, we conducted a retrospective comparative study of biopsy-proven stage I RCC patients treated with SABR or RFA at a single tertiary institution, with evaluation of oncologic outcomes, toxicities and renal function preservation while accounting for baseline imbalances between treatment groups. Materials and Methods This retrospective study included patients with biopsy-proven T1N0M0 RCC treated with either SABR or RFA between May 2009 and March 2024 at a single institution. Patients were excluded if they had no histologic confirmation, biopsy-proven urothelial carcinoma, renal pelvis tumors, recurrent disease, bilateral lesions, or were lost to follow-up before adequate post-treatment assessment. The study was approved by the Institutional Review Board of the participating institution (No. 2024-1170). The requirement for informed consent was waived for this retrospective study. Patients in the SABR group were treated using CyberKnife ver. 9.5. (Accuray Inc., Sunnyvale, CA, USA). Three gold fiducial markers were percutaneously placed around the tumor for real-time tracking with the Synchrony respiratory motion management system. Three-dimensional CT simulation was performed under end-expiratory breath-hold using a non-contrast CT with 1.25 mm slice thickness. Contrast-enhanced CT and/or MRI were co-registered for gross tumor volume (GTV) delineation. The planning target volume (PTV) was generated by expanding GTV by 3 mm. Treatment planning was conducted with Multipan ver. 4.5 (Accuray Inc.) using a ray-tracing algorithm with a fixed cone ranging from 5 to 60 mm. Stereotactic radiotherapy was prescribed to 80–95% isodose line covering ≥ 95% of the PTV and delivered every other day. Fractionation was selected based on the proximity of the target adjacent to bowel structures, with 42 Gy in 3 fractions used when bowel dose constraints could be met and 35 Gy in 5 fractions used when proximity was close. Organ at risk dose constraints followed the report by Timmerman [10]. RFA was performed percutaneously under CT guidance by experienced radiologists, each with a minimum of 5 years of experience. Local anesthesia and analgesia were administered as needed. A 17-gauge internally cooled monopolar electrode was used. For tumors close to adjacent bowel, hydrodissection was performed to ensure a safety margin. Ablation was conducted for at least 10–12 min per lesion, followed by tract cauterization to minimize bleeding and seeding. Each patient received a single session of RFA as their initial treatment. Patients underwent imaging follow-up with contrast-enhanced CT or MRI, with an initial evaluation at 3 months after treatment and subsequent follow-up performed at approximately 612 month intervals. Renal function was evaluated using estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration formula at each visit. Treatment-related toxicities were graded using Common Terminology Criteria for Adverse Events version 5.0. Study endpoints included freedom from local recurrence (FFLR), disease-free survival (DFS), overall survival (OS), longitudinal eGFR change, treatment-related toxicities, and the incidence of sustained eGFR < 15 mL/min/1.73 m2 for ≥ 3 months or dialysis. After SABR, local recurrence (LR) was defined as progressive disease within the ipsilateral kidney, assessed according to Response Evaluation Criteria in Solid Tumors version 1.1. After RFA, LR was defined as the development of new or enlarging contrast-enhancing lesions within or adjacent to the ablation zone. Regional recurrence was defined as regional lymph node metastasis. FFLR, DFS, and OS were estimated using the Kaplan-Meier method. To address baseline imbalances, inverse probability of treatment weighting (IPTW) was performed using propensity scores estimated from age, sex, tumor size, baseline eGFR, and history of other malignancy diagnosed within 5 years, comorbidity status (diabetes, hypertension, cardiovascular or cerebrovascular disease), tumor location, and proximity to renal sinus or collecting system. Tumor location was categorized according to the component of the R.E.N.A.L. nephrometry score as anterior, posterior, or indeterminate [11]. Proximity to the renal sinus or collecting system was dichotomized based on the N component (≤4 mm vs. > 4 mm). Stabilized IPTW were calculated to estimate the average treatment effect, with propensity scores trimmed at the 1st and 99th percentiles. Covariate balance was evaluated using absolute standardized mean differences (SMD; <0.1 ideal, <0.2 acceptable). IPTW-adjusted Cox proportional hazards models with robust standard errors evaluated associations between treatment and outcomes. Subgroup analyses were performed according to age, sex, tumor size, pretreatment eGFR, tumor location, renal sinus proximity, history of other malignancy, and comorbidity status using IPTW weights derived from the overall propensity score model, and treatment-by-subgroup interactions were tested in IPTW-weighted Cox models. Longitudinal renal function change was defined as follow-up eGFR minus baseline eGFR. Patients with baseline eGFR < 15 mL/min/1.73 m2 were excluded, as were measurements obtained after sustained eGFR < 15 mL/min/1.73 m2 or dialysis. IPTW-weighted linear mixed-effects models were fitted with treatment group, time, and their interaction as fixed effects. Time was modeled categorically at 12, 24, 36, 48, and 60 months (windows: 6 to < 18, 18 to < 30, 30 to < 42, 42 to < 54, 54 to < 72 months) with a random intercept per patient, and continuously to estimate the annual rate of eGFR decline with random intercepts and random slopes per patient. All statistical analyses were performed using Python (version 3.13.5) and R (version 4.4.3). Results A total of 123 patients with biopsy-proven stage I RCC were included in the analysis (SABR, n = 54; RFA, n = 69). In the SABR group, most patients were treated with 42 Gy in 3 fractions (n = 39), followed by 35 Gy in 5 fractions (n = 12), while 32 Gy in 4 fractions (n = 1), 45 Gy in 3 fractions (n = 1), and 48 Gy in 4 fractions (n = 1) were also used. Baseline characteristics are summarized in Table 1. SABR group had a significantly higher mean age (75 vs. 69 years, p = 0.002) and larger tumor size (2.5 ± 0.9 vs. 1.9 ± 0.6 cm, p < 0.001) compared to the RFA group. Tumor location distribution differed significantly between groups (p = 0.008). Anterior tumors were more common in the SABR group (31.5% vs. 24.6%), whereas posterior tumors were less common (46.3% vs. 69.6%). Renal sinus proximity of ≤ 4 mm was more frequently observed in the SABR group (59.3% vs. 34.8%, p = 0.012). In addition, baseline eGFR was significantly lower in the SABR group (65.2 ± 24.0 vs. 78.4 ± 21.9 mL/min/1.73 m2, p = 0.002).Table 1Baseline characteristics.CharacteristicSABR (n = 54)RFA (n = 69)p-valueAge (years)75 ± 1069 ± 110.002SexM40 (74.1)48 (69.6)0.727F14 (25.9)21 (30.4)Other malignancy within 5 yearsNo40 (74.1)51 (73.9)1.000Yes14 (25.9)18 (26.1)Any comorbidityNo9 (16.7%)18 (26.1%)0.274Yes45 (83.3%)51 (73.9%)T stageT1a49 (90.7)69 (100.0)0.034T1b5 (9.3)0 (0.0)Tumor size (cm)2.5 ± 0.91.9 ± 0.6<0.001Tumor locationAnterior17 (31.5)17 (24.6)0.008Posterior25 (46.3)48 (69.6)Indeterminate12 (22.2)4 (5.8)Renal sinus proximity≤4 mm32 (59.3)24 (34.8)0.012>4 mm22 (40.7)45 (65.2)Pretreatment eGFR (mL/min/1.73 m2)65.2 ± 24.078.4 ± 21.90.002Comparison between groups was performed using the student’s t-test for continuous variables and chi-squared test for categorical variables. Fisher’s exact test was applied when the expected cell count was less than 5.Abbreviations: SABR, Stereotactic ablative body radiotherapy; RFA, Radiofrequency ablation; eGFR, Estimated glomerular filtration rate. Table 1Baseline characteristics.CharacteristicSABR (n = 54)RFA (n = 69)p-valueAge (years)75 ± 1069 ± 110.002SexM40 (74.1)48 (69.6)0.727F14 (25.9)21 (30.4)Other malignancy within 5 yearsNo40 (74.1)51 (73.9)1.000Yes14 (25.9)18 (26.1)Any comorbidityNo9 (16.7%)18 (26.1%)0.274Yes45 (83.3%)51 (73.9%)T stageT1a49 (90.7)69 (100.0)0.034T1b5 (9.3)0 (0.0)Tumor size (cm)2.5 ± 0.91.9 ± 0.6<0.001Tumor locationAnterior17 (31.5)17 (24.6)0.008Posterior25 (46.3)48 (69.6)Indeterminate12 (22.2)4 (5.8)Renal sinus proximity≤4 mm32 (59.3)24 (34.8)0.012>4 mm22 (40.7)45 (65.2)Pretreatment eGFR (mL/min/1.73 m2)65.2 ± 24.078.4 ± 21.90.002Comparison between groups was performed using the student’s t-test for continuous variables and chi-squared test for categorical variables. Fisher’s exact test was applied when the expected cell count was less than 5.Abbreviations: SABR, Stereotactic ablative body radiotherapy; RFA, Radiofrequency ablation; eGFR, Estimated glomerular filtration rate. Baseline characteristics. Comparison between groups was performed using the student’s t-test for continuous variables and chi-squared test for categorical variables. Fisher’s exact test was applied when the expected cell count was less than 5. Abbreviations: SABR, Stereotactic ablative body radiotherapy; RFA, Radiofrequency ablation; eGFR, Estimated glomerular filtration rate. At a median follow-up of 46.3 months (range, 5.0–148.4), baseline characteristics including age, sex, tumor size, pretreatment eGFR, and history of other malignancy, comorbidity status, tumor location, and close renal sinus proximity (≤4 mm) were well-balanced after IPTW (all absolute SMD ≤ 0.15; Supplementary Table 1). In IPTW-adjusted Cox proportional hazard models, no significant differences were observed between the SABR and RFA groups for FFLR (Hazard ratio [HR] = 0.75, 95% confidence interval [CI]: 0.15–3.88; p = 0.733, with RFA as the reference), DFS (HR = 0.98, 95% CI: 0.47–2.08; p = 0.965), and OS (HR = 0.86, 95% CI: 0.37–2.01; p = 0.724). The corresponding IPTW-adjusted 3-year outcomes for SABR vs. RFA were 98.8% vs. 91.6% for FFLR, 78.5% vs. 79.3% for DFS, and 82.4% vs. 87.9% for OS, respectively (Fig. 1). In unadjusted analyses, 3-year FFLR rates were 97.7% for SABR and 93.3% for RFA (p = 0.806), with 3-year DFS of 83.3% vs 85.9% (p = 0.546), and OS of 86.7% and 92.5% (p = 0.979), respectively (Supplementary Fig. 1).Fig. 1IPTW-weighted Kaplan–Meier curves according to treatment group. (A) Freedom from local recurrence, (B) Disease-free survival, and (C) Overall survival.Abbreviations: SABR, stereotactic ablative body radiotherapy; RFA, radiofrequency ablation. IPTW-weighted Kaplan–Meier curves according to treatment group. (A) Freedom from local recurrence, (B) Disease-free survival, and (C) Overall survival.Abbreviations: SABR, stereotactic ablative body radiotherapy; RFA, radiofrequency ablation. LRs occurred in three SABR patients and seven RFA patients. All three SABR recurrences occurred after 35 Gy in 5 fractions, at 17.8, 56.0, and 68.3 months, in anteriorly located tumors measuring 1.6, 1.9, and 2.6 cm; two had renal sinus proximity ≤ 4 mm. Among the seven RFA recurrences, tumor size ranged from 1.4 to 3.5 cm (median, 2.2 cm); six tumors were posteriorly located and three had renal sinus proximity ≤ 4 mm. Regional recurrence occurred in two SABR patients at 2.7 and 29.7 months, whereas no regional recurrence was observed in the RFA group. The early regional recurrence at 2.7 months involved a paraaortic lymph node that had been visible on baseline imaging but was classified as cN0 according to imaging criteria at the time of treatment. Distant metastasis developed in one patient in each group: at 30.0 months in the SABR group following sequential local and regional recurrence, and at 54.5 months in the RFA group without prior local or regional recurrence. Subgroup analyses are presented in Supplementary Fig. 2. A significant treatment-by-age interaction was observed for OS (p = 0.013, Supplementary Fig. 2C), with SABR associated with a lower hazard of overall mortality in patients aged > 75 years compared with RFA (HR 0.27, 95% CI 0.09–0.83), whereas no significant difference was observed in patients aged ≤ 75 (HR 2.04, 95% CI 0.69–6.03). A similar trend was observed for DFS (p = 0.087, Supplementary Fig. 2B). A significant interaction by comorbidity status was identified for DFS (p = 0.002) and in patients without comorbidity, outcomes favored RFA (HR 3.37, 95% CI 1.19–9.51). An interaction by history of other malignancy was also observed for OS (p = 0.045), although subgroup-specific HRs were not statistically significant. Subgroup analyses for FFLR were limited by the small number of events (n = 10) and are shown in Supplementary Fig. 2A. No grade ≥ 3 toxicities directly attributable to radiation itself were observed. One grade 3 bleeding event related to fiducial marker insertion occurred in the SABR group and required embolization and transfusion. One patient in the RFA group experienced grade 2 acute pneumothorax. No grade ≥ 2 non-renal toxicities were observed in SABR group. Sustained eGFR < 15 mL/min/1.73 m2 or dialysis occurred in 2 patients (4.0%) in the SABR group and 3 patients (4.4%) in the RFA group among patients with baseline eGFR ≥ 15 mL/min/1.73 m2. After IPTW adjustment, no significant difference was observed between groups (HR, 0.36; 95% CI, 0.06–2.32; p = 0.282), with a numerically lower hazard in the SABR. Corresponding Kaplan–Meier curves are provided in Supplementary Fig. 3. In a random coefficient model, the overall annual eGFR decline was comparable between the SABR and RFA groups (–2.1 vs. –1.3 mL/min/1.73 m2 per year, respectively; p = 0.364). Serial analyses demonstrated comparable mean eGFR reductions at all follow-up time points (Fig. 2 and Table 2). At 12 months, the mean eGFR reduction was –8.2 mL/min/1.73 m2 (95% CI, –11.3 to –5.2) in the SABR group and –6.7 mL/min/1.73 m2 (95% CI, –9.4 to –4.1) in the RFA group (p = 0.459). At subsequent follow-up times (24, 36, 48, and 60 months), mean eGFR changes continued to be comparable between the SABR and RFA groups: –10.4 vs. –7.4 at 24 months (p = 0.158), –13.3 vs. –10.8 at 36 months (p = 0.260), –13.6 vs. –9.8 at 48 months (p = 0.148), and –12.2 vs. –12.2 mL/min/1.73 m2 at 60 months (p = 0.982), respectively.Fig. 2IPTW-weighted mean changes in eGFR according to the treatment group (SABR vs. RFA).Abbreviations: eGFR, estimated glomerular filtration rate; SABR, Stereotactic ablative body radiotherapy; RFA, Radiofrequency ablation. Vertical bars represent 95% confidence intervals.Table 2IPTW-adjusted mean eGFR change from baseline by treatment group over time.Follow-upTreatmentMean (95% CI) (mL/min/1.73 m2)SEp-value12 monthsSABR−8.2 (−11.3, −5.2)1.530.459RFA−6.7 (−9.4, −4.1)1.3324 monthsSABR−10.4 (−13.6, −7.2)1.620.158RFA−7.4 (−10.1, −4.7)1.3936 monthsSABR−13.3 (−16.7, −10.0)1.680.260RFA−10.8 (−13.7, −7.9)1.4748 monthsSABR−13.6 (−17.8, −9.4)2.120.148RFA−9.8 (−12.8, −6.9)1.5060 monthsSABR−12.2 (−16.6, −7.8)2.240.982RFA−12.2 (−15.3, −9.0)1.59Estimated using IPTW-weighted linear mixed-effects models.Abbreviations: eGFR = estimated glomerular filtration rate; SE = standard error; CI = confidence interval; SABR = stereotactic ablative body radiotherapy; RFA = radiofrequency ablation. IPTW-weighted mean changes in eGFR according to the treatment group (SABR vs. RFA).Abbreviations: eGFR, estimated glomerular filtration rate; SABR, Stereotactic ablative body radiotherapy; RFA, Radiofrequency ablation. Vertical bars represent 95% confidence intervals. Table 2IPTW-adjusted mean eGFR change from baseline by treatment group over time.Follow-upTreatmentMean (95% CI) (mL/min/1.73 m2)SEp-value12 monthsSABR−8.2 (−11.3, −5.2)1.530.459RFA−6.7 (−9.4, −4.1)1.3324 monthsSABR−10.4 (−13.6, −7.2)1.620.158RFA−7.4 (−10.1, −4.7)1.3936 monthsSABR−13.3 (−16.7, −10.0)1.680.260RFA−10.8 (−13.7, −7.9)1.4748 monthsSABR−13.6 (−17.8, −9.4)2.120.148RFA−9.8 (−12.8, −6.9)1.5060 monthsSABR−12.2 (−16.6, −7.8)2.240.982RFA−12.2 (−15.3, −9.0)1.59Estimated using IPTW-weighted linear mixed-effects models.Abbreviations: eGFR = estimated glomerular filtration rate; SE = standard error; CI = confidence interval; SABR = stereotactic ablative body radiotherapy; RFA = radiofrequency ablation. IPTW-adjusted mean eGFR change from baseline by treatment group over time. Estimated using IPTW-weighted linear mixed-effects models. Abbreviations: eGFR = estimated glomerular filtration rate; SE = standard error; CI = confidence interval; SABR = stereotactic ablative body radiotherapy; RFA = radiofrequency ablation. Discussion In this study, SABR and RFA demonstrated comparable oncologic and renal outcomes after IPTW adjustment. These findings suggest that SABR achieves oncologic efficacy and renal preservation comparable to RFA, despite being applied in an older population with larger tumors and poorer baseline renal function, supporting its role as a viable treatment alternative to RFA. To date, high-level comparative evidence between SABR and RFA remains limited. The RADSTER trial is the only study that directly compared the two modalities within the same cohort; however, its small sample size (SABR, n = 14; RFA, n = 7) and short follow-up preclude definitive conclusions, despite no local failure, metastasis, or death at 1 year [12]. An International Society of Stereotactic Radiosurgery (ISRS) review reported favorable oncologic outcomes after SABR, with a median local control rate of 94.1% and 5-year progression-free survival of 80.5% [8]. Similarly, a meta-analysis demonstrated high and comparable local control for SABR and RFA (5-year local control, 95% vs. 92%) despite larger tumor in SABR group (3.9 vs 2.8 cm) [4]. In this context, the present study represents the largest direct comparison of SABR and RFA to date, demonstrating comparable oncologic outcomes after adjustment for baseline imbalances. In subgroup analyses, a significant treatment-by-age interaction was observed for OS, with SABR associated with a lower hazard of overall mortality among patients aged > 75 years, whereas no significant difference was noted in younger patients. Given that SABR is less invasive than RFA, this modality may offer advantages in elderly or frail individuals. However, interactions were also identified according to comorbidity status and history of other malignancy, suggesting potential heterogeneity of treatment effects. These findings should be interpreted cautiously, as the subgroup analyses were exploratory and not powered for definitive comparisons. Tumor location and size influence modality selection, and SABR may be advantageous in challenging cases for RFA. For RFA, reduced local control has been reported for tumors larger than 3–3.5 cm and for centrally located lesions due to heat sink effects, with higher complication rates observed in central tumors adjacent to the proximal ureter or major vessels [13], [14], [15]. In contrast, SABR is not subject to heat sink effects, and our results showed comparable oncologic outcomes despite larger and centrally located tumors. In addition, anterior tumors, which are considered technically challenging for percutaneous ablation [16], were more frequently managed with SABR. Although bowel adjacency can pose planning challenges for SABR, dose fractionation and contemporary image-guided techniques generally enable safe delivery. In the SABR group, all three LRs occurred after 35 Gy in 5 fractions, whereas no LR was observed after 42 Gy in 3 fractions. The prospective FASTRACK II trial achieved 100% 12-month local control using either 26 Gy in a single fraction or 42 Gy in 3 fractions [17]. Similarly, the IROCK individual patient data meta-analysis, which included multifraction SABR regimens ranging from 2 to 10 fractions (median prescription, 42 Gy in 4 fractions), demonstrated a significantly higher risk of local failure with multifraction versus single-fraction SABR (HR 6.10, 95% CI 1.02–36.66) [18]. Consistent with these findings, our results suggest that 35 Gy in 5 fractions may provide less durable local control than 42 Gy in 3 fractions. Response assessment after SABR is challenging because treated RCC lesions often remain radiographically stable or regress slowly rather than showing rapid resolution. Prospective studies have demonstrated limited tumor shrinkage at approximately 1 year after SABR [8], and volumetric assessment may better reflect post-SABR response than linear measurements [19]. Biopsy specimens of residual lesions demonstrated biologic effects of SABR, including reduced tumor cellularity, decreased proliferative activity, and molecular features consistent with treatment-induced cellular senescence [20], [21]. Although residual tumor was commonly identified on biopsies performed 6–12 months after SABR, these findings did not correlate with subsequent radiographic progression or treatment failure [20], [22], [23]. Accordingly, the ISRS guideline and prospective studies recommend that post-SABR response assessment should not rely solely on size-based criteria [8], [9]. Given the low rates (2–3%) of severe toxicities reported for both SABR and RFA in localized RCC [4], [8], preservation of renal function remains a key endpoint. Prior meta-analyses reported 1-year eGFR declines, demonstrating no significant differences between SABR (6.0–6.7 mL/min/1.73 m2) and RFA (4.9 mL/min/1.73 m2) [4], [24]. Similarly, the RADSTER trial demonstrated comparable 1-year eGFR reductions (RFA − 3.0 vs. SABR − 5.3 mL/min/1.73 m2; p = 0.7) [12], but baseline renal function was not adjusted. In the present study, after IPTW adjustment to account for baseline imbalances—particularly the lower baseline eGFR in the SABR group—no significant differences were observed in the incidence of kidney failure or in longitudinal renal function changes between SABR and RFA. Both treatments demonstrated a similar pattern of early eGFR decline followed by stabilization over time. This study has several limitations, including its retrospective single-center design and relatively small sample size. Toxicities assessment was largely limited to objectively measurable parameters such as renal function because documentation of non-renal or patient-reported toxicities was frequently incomplete. Cancer-specific survival was not evaluated because causes of death could not be reliably determined from the available records; therefore, DFS was used instead. Although the median follow-up was sufficient to assess early oncologic and renal outcomes, it may not capture very late recurrences or renal deterioration. In addition, treatment selection was non-randomized and likely influenced by tumor characteristics and physician preference, although IPTW was applied to reduce confounding. Despite these limitations, this study represents, to our knowledge, the largest direct comparison of SABR and RFA in biopsy-proven primary RCC. Further prospective studies with longer follow-up are warranted. Conclusion SABR demonstrated excellent local control and favorable renal function preservation in patients with stage I RCC, with outcomes comparable to those of RFA. These findings support SABR as an effective local treatment option for patients who are not suitable candidates for surgery. CRediT authorship contribution statement Ye Jin Yoo: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. Lim Jiyoon: Investigation, Data curation. Kye Jin Park: Supervision, Data curation. Cheryn Song: Writing – review & editing, Supervision, Data curation. Yeon Joo Kim: Writing – review & editing, Writing – original draft, Supervision, Data curation, Conceptualization. Young Seok Kim: Writing – review & editing, Supervision, Conceptualization. Funding This study was supported by a grant (grant number 2025IT0008-1) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.